Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


7TM Pharma adds Johnson & Johnson Development Corporation to its investor group
Announces the selection of a new development candidate for treatment of obesity

Denmark - August 18, 2005:
7TM Pharma has expanded its investor base by including Johnson & Johnson Development Corporation (JJDC) as investor in the company. The size of the investment is not disclosed.

The proceeds from JJDC’s investment combined with investments from current investors as well as revenues from collaborative agreements will be used to advance 7TM Pharma’s development and discovery programs with a focus on metabolic disorders.

'We are very pleased to include JJDC as investor in 7TM Pharma,' says Mette Kirstine Agger, CEO of 7TM Pharma. 'We have a strong investor group that is supporting us continuously and JJDC will provide an excellent contribution to this group'.

7TM Pharma’s other investors include Alta Partners, Index Ventures, Novo A/S, Dansk Innovationsinvestering, Lombard Odier Darier Hentsch & Cie, and Baker/Tisch Investment.

Selection of new development candidate
7TM Pharma has established a platform of Y receptor agonists with different pharmacological properties and has earlier this summer announced the initiation of phase I/II clinical trials with the compound TM30338. 7TM Pharma has now selected another compound - TM30339 - from its Y receptor program and initiated pre-clinical development preparing for clinical development to test the compound for the treatment of obesity.

7TM Pharma’s Y receptor peptides have been developed using the company’s structure-based drug discovery approach as well as world-leading expertise within the Y receptor field. Two distinct types of Y receptors have been validated in man as appetite suppressive drug targets using natural hormones; TM30339, the new pre-clinical candidate, is highly selective and targets one of the appetite suppressive receptors. In diet-induced obese animals TM30339 has demonstrated a pharmacological profile different from TM30338 and shown clear effect with respect to long term reduction of food intake and weight loss.

Obesity is considered a major health problem and challenge to the developed world as it significantly increases the risk of cardiovascular diseases and diabetes type II, resulting in enormous health care expenditure costs. There are more than 300 mill clinically obese people with a BMI above 30 and the number is growing rapidly. Despite this, the treatment of obesity is currently restricted to a few drugs with limited efficacy and there is an urgent need for new and improved treatment possibilities.

'It is an important broadening of the scope of our Y receptor agonist program to also move TM30339 into development.' says Thue W. Schwartz, CSO of 7TM Pharma. 'Being able to initiate development of 2 compounds within a year once again confirms the capacity of our organization and our drug discovery team.'

Within its Y receptor program, 7TM Pharma has generated several series of proprietary peptides with different modes of action targeting different Y receptors. These peptides have potential as new therapeutics not only in the treatment of obesity and associated diseases such as diabetes, but also in cardiovascular diseases. Earlier this year the company announced a research agreement with Procter & Gamble Pharmaceuticals, Inc., a subsidiary of The Procter & Gamble Company (NYSE: PG), under which the parties undertake a joint research program within therapeutic angiogenesis – generation of new blood vessels - with the aim of identifying peptide drug candidates for the treatment of diseases such as peripheral vascular diseases and coronary vascular disease related to arteriosclerosis.

During the past 1˝ years, 7TM Pharma has expanded its pipeline significantly and through 2005 the efficiency and quality of 7TM Pharma’s drug discovery capabilities has been further validated through two deals with major pharmaceutical companies – including the recent discovery collaboration with Ortho-McNeil, Inc., a Johnson & Johnson company, to develop novel compounds for the treatment of asthma and allergic diseases.

Publisher Contact Information:

7TM Pharma A/S
+45 39 25 77 77

Company profile of 7TM Pharma A/S
Past press releases of 7TM Pharma A/S.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
May 30€15.0MBiopharmaceuticals
May 28€15.0MDiagnostics
May 28€1.3MInternet services
May 25€1.0MOther Software
May 22N/AInternet services
May 20€4.3MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.